Why Eli Lilly and Company (LLY) is the Best Long-Term Growth Stock to Buy Now
We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...
Ozempic shown to reduce drinking in first trial in alcohol-use disorder
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...
BioSpace16h
Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...
Irish Examiner12h
Innovating beyond boundaries: Sarah O’Keeffe’s career in making medicine
Sarah O’Keeffe recounts her fulfilling career path with Eli Lilly from employee to Senior Vice President, Product Research ...
MM&M4h
How new direct-to-consumer platforms are changing pharma’s relationships with patients
New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with patients.
Health Rounds: Hormone delivery via skin patch may ease prostate cancer treatment side effects
When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...
Diet drug boom weighs heavily on state budgets
The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...
MarketBeat on MSN8h
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...
Pharma companies turn to AI to speed up drug development, but hit hurdles
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
FiercePharma1h
‘We cannot stay silent’: Novo Nordisk flags dangers of compounded GLP-1s following Hims & Hers Super Bowl ad
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...
PepsiCo, Inc. (PEP): Jim Cramer Calls It “A Tried and True Dividend Aristocrat”
We recently published a list of 17 Best Stocks for Kids According to Jim Cramer. In this article, we are going to take a look ...
Three reasons Nvidia's stock is still compelling, and why it could rise 30% in the next year
We ran that screen on Feb. 15 last year, using data as of the market close the previous day. Nvidia's (NVDA) stock has returned 80% from Feb. 14, 2024, through Tuesday, while the S&P 500 SPX has ...